Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 2, 2012, Pages 221-223

  Pierre Audigier, C ^a   Surcouf, C ^b   Cadet Daniel, V ^a   Namouchi, A ^a   Heng, S ^b   Murray, A ^a   Guillard, B ^b   Gicquel, B ^a  

^a INSTITUT PASTEUR   (France)

^b INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

Fluoroquinolone; MDR TB; Pyrazinamide

Indexed keywords

PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CAMBODIA; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GYRA GENE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; RPOB GENE; SEQUENCE ANALYSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; CAMBODIA; DNA, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; INCIDENCE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84855706343     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0266     Document Type: Article

References (10)

1. Espinal M, Raviglione M C. From threat to reality: the real face of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 216-217.
2. World Health Organization. Global tuberculosis control. WHO report 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
3. Caminero J A, Sotgiu G, Zumla A, Migliori G B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
4. Ando H, Mitarai S, Kondo Y, et al. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in J apan. Clin Microbiol Infect 2010; 16: 1164-1168.
5. Louw G E, Warren R M, Donald P R, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802-807. (Pubitemid 44031396)
6. Saravia J C, Appleton S C, Rich M L, Sarria M, Bayona J, Becerra M C. Retreatment management strategies when fi rstline tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-429. (Pubitemid 40524034)
7. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21. (Pubitemid 36427026)
8. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-667. (Pubitemid 26191953)
9. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G F, Jacobs W R, eds. Molecular genetics of mycobacteria. Washington DC, USA: ASM Press, 2000: pp 235-254.
10. Minime-Lingoupou F, Pierre-Audigier C, Kassa-Kélémbho E, et al. Rapid identifi cation of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. Int J Tuberc Lung Dis 2010; 14: 782-785.